Clinical and laboratory findings of COVID-19: A systematic review and meta-analysis

Khamis, Amar Hassan; Jaber, Mohamed; Azar, Aïda J.; AlQahtani, Feras AlMofreh; Bishawi, Khaled; Shanably, Ahmed

doi:10.1016/j.jfma.2020.12.003

Cited by 17 publications

(18 citation statements)

References 66 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Previous studies reported that children with COVID‐19 were hospitalized less frequently than adults with COVID‐19; furthermore, fewer children with COVID‐19 experienced fever, cough, or shortness of breath. 11 , 14 Khamis et al 15 compiled the clinical characteristics of adult patients and showed that the fatality rate was 10.5%.…”

Section: Discussionmentioning

confidence: 99%

Epidemiological characteristics and clinical manifestations of pediatric patients with COVID‐19 in China: A multicenter retrospective study

Gao

Wang

Zhao

et al. 2021

Pediatric Investigation

View full text Add to dashboard Cite

Importance The Coronavirus disease 2019 (COVID‐19) global pandemic poses a considerable challenge for pediatricians. Objective This study aimed to identify the epidemiological characteristics and clinical features of pediatric patients with COVID‐19 in China. Methods This multicenter retrospective study included pediatric patients from 46 hospitals in China, covering 12 provinces and two municipalities. Epidemiological, demographic, clinical, laboratory, treatment, and outcome data were analyzed. Results In total, 211 pediatric patients with COVID‐19 were included in this study. The median age was 7.0 years (range: 22 days to 18 years). Approximately 16.3% of the patients exhibited asymptomatic infections, 23.0% had upper respiratory tract infections, and 60.7% had pneumonia, including two with severe pneumonia and one with critical illness. Approximately 78.7% of the pediatric patients occurred in familial clusters. The most three common symptoms or signs at onset in children with COVID‐19 were fever (54.5%), cough (49.3%), and pharyngeal congestion (20.8%). Only 17.6% of the patients presented with decreased lymphocyte count, whereas 13.6% had increased lymphocyte count. Among the patients with pneumonia who exhibited abnormal chest computed tomography findings, 18.2% (23/127) of the patients had no other symptoms. Generally, the chest radiographs showed abnormalities that affected both lungs (49.6%); ground‐glass opacity (47.2%) was the most common manifestation. The cure and improvement rates were 86.7% (183/211) and 13.3% (28/211), respectively. Only one patient with an underlying condition received invasive mechanical ventilation; none of the patients died. Interpretation Similar to adults, children of all age groups are susceptible to COVID‐19. Fortunately, most pediatric patients have mild symptoms or remain asymptomatic, despite the high incidence of pneumonia. Decreased proportions of white blood cells and lymphocytes are less frequent in children than in adults.

show abstract

Section: Discussionmentioning

confidence: 99%

Epidemiological characteristics and clinical manifestations of pediatric patients with COVID‐19 in China: A multicenter retrospective study

Gao

Wang

Zhao

et al. 2021

Pediatric Investigation

View full text Add to dashboard Cite

show abstract

“…Furthermore, the different and somewhat discrepant symptoms of COVID-19, including the musculoskeletal ones, difficult the prognostic of the disease, and SARS-CoV-2 viral infection versus musculoskeletal symptomatology is still a subject poorly investigated and a challenge to the researchers in the Muscle Physiology field. Interestingly, some studies highlighted that laboratory findings (elevated levels of CK, LDH, C-reactive protein, creatinine, D-dimer and cytokines; lymphopenia and leukocytosis) and imaging tools (computed tomography—CT scan; magnetic resonance imaging—MRI; positron emission tomography—PET; ultrasound; radiography) can play a crucial role in the prognosis, diagnosis and evaluation of the manifestations of COVID-19, supporting a better treatment of the patients ( Feng et al, 2020 ; Ghayda et al, 2020 ; Orsucci, 2020 ; Ponti et al, 2020 ; Revzin et al, 2020 ; Afshar-Oromieh et al, 2021 ; Akbar et al, 2021 ; Capaccione et al, 2021 ; Chopra et al, 2021 ; Khamis et al, 2021 ; Meng et al, 2021 ; Ramani et al, 2021 ; Xie et al, 2021 ). Unfortunately, the majority of the laboratory and imaging techniques focus on the respiratory, cardiac, gastrointestinal and neurologic systems, and few findings are related to the musculoskeletal apparatus.…”

Section: The Musculoskeletal Symptomatologymentioning

confidence: 99%

The Musculoskeletal Involvement After Mild to Moderate COVID-19 Infection

et al. 2022

View full text Add to dashboard Cite

COVID-19, a disease caused by the novel coronavirus SARS-CoV-2, has been drastically affecting the daily lives of millions of people. COVID-19 is described as a multiorgan disease that affects not only the respiratory tract of infected individuals, but it has considerable effects on the musculoskeletal system, causing excessive fatigue, myalgia, arthralgia, muscle weakness and skeletal muscle damage. These symptoms can persist for months, decreasing the quality of life of numerous individuals. Curiously, most studies in the scientific literature focus on patients who were hospitalized due to SARS-CoV-2 infection and little is known about the mechanism of action of COVID-19 on skeletal muscles, especially of individuals who had the mild to moderate forms of the disease (non-hospitalized patients). In this review, we focus on the current knowledge about the musculoskeletal system in COVID-19, highlighting the lack of researches investigating the mild to moderate cases of infection and pointing out why it is essential to care for these patients. Also, we will comment about the need of more experimental data to assess the musculoskeletal manifestations on COVID-19-positive individuals.

show abstract

“…A systematic review including 36 articles showed that COVID-19 status alone was a common indication for caesarean delivery early in the pandemic, despite a lack of evidence regarding vertical transmission. This increase in the rate of caesarean delivery may reflect obstetricians' attempts to save the life of their patients under constantly evolving guidelines [2].…”

Section: Fig 2 Kaplan-meier Survival Curve For Patients Treated By Re...mentioning

confidence: 99%

“…The emergence and rapid spread of the novel coronavirus SARS-CoV-2, which causes the disease COVID-19, led to declaration of a global pandemic by the World Health Organization (WHO) in March 2020 [1]. Patients with COVID-19 infection show a wide range of clinical features [2]. The knowledge gained from previous human coronavirus outbreaks suggests that in specific situations such as pregnancy, women infected with SARS-CoV-2 are prone to having a higher risk for infection-related respiratory complications in comparison with non-pregnant women [3].…”

Section: Introductionmentioning

confidence: 99%

Remdesivir Therapy versus Standard Care in Hospitalized Pregnant Women with Moderate and Severe COVID-19 in a Tertiary Care Center of Dubai: A Quasi-experimental Study

Ali

Harab

Hazari

et al. 2022

AJRID

Self Cite

View full text Add to dashboard Cite

Background: Pregnant women with COVID-19 are more likely to be hospitalized and require respiratory support than non-pregnant women. There is little published data on Remdesivir use in pregnant women with COVID-19. We aimed to investigate the clinical course and obstetric outcomes for pregnant women with COVID-19 administered Remdesivir versus standard therapy. Methods: We conducted a non-randomized quasi experimental study among 100 pregnant women with moderate or severe COVID-19 who were admitted to a tertiary care hospital in Dubai between 18 January and 31 March 2021. We compared women receiving Remdesivir (treatment arm) and women receiving standard therapy (control arm). Results: More women in the Remdesivir group had normal vaginal delivery (n=17, 39.5%) than controls (n=9, 20.5%). Newborn Apgar scores at 1 and 5 minutes were similar in both groups. The mean standard deviation time to recovery and discharge was lower for patients receiving Remdesivir than controls (8.4\(\pm\)3.3 versus 13.6\(\pm\)9.2 days). Fewer treated patients required intensive care; at 60- day follow-up, all women on Remdesivir were doing well whereas six (12.0%) women on standard therapy had died. Conclusions: Pregnant women with moderate or severe COVID-19 treated early with Remdesivir showed an overall better clinical course and outcomes than those on standard therapy.

show abstract

Clinical and laboratory findings of COVID-19: A systematic review and meta-analysis

Cited by 17 publications

References 66 publications

Epidemiological characteristics and clinical manifestations of pediatric patients with COVID‐19 in China: A multicenter retrospective study

Epidemiological characteristics and clinical manifestations of pediatric patients with COVID‐19 in China: A multicenter retrospective study

The Musculoskeletal Involvement After Mild to Moderate COVID-19 Infection

Remdesivir Therapy versus Standard Care in Hospitalized Pregnant Women with Moderate and Severe COVID-19 in a Tertiary Care Center of Dubai: A Quasi-experimental Study

Contact Info

Product

Resources

About